Before today's news.
Novartis partnership takes it to .50.
Read today's Yahoo news.
Tremendously undervalued at under a dime.
More upside than MNKD.
Tremendous potential in the field of diabetes.
Under a dime currently.
Jason Napadano rates it's a "BUY" and his price target offers 400% upside.
Currently trading under a dime with a $25M market cap.